Access cutting-edge prostate cancer treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.
Access prostate cancer specialists in Los Angeles at no cost
This study follows strict safety protocols and ethical guidelines
All study-related prostate cancer treatment provided free
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androg
Sponsor: Novartis Pharmaceuticals
Check if you qualify for this prostate cancer clinical trial in Los Angeles, CA
If you're searching for prostate cancer treatment options in Los Angeles, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.